|Systematic (IUPAC) name|
|Molar mass||400.518 g/mol[[Script error: No such module "String".]]|
Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. Synta Pharmaceuticals announced on February 26, 2009 the suspension of all clinical trials involving Elesclomol due to safety concerns.. In March 2010, Synta announced that the FDA had approved resuming clinical development of elesclomol, and that they expected to initiate one or more clinical trials for elesclomol in the second half of the year.
Mechanism of action
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|40px||This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it.|
- "Synta And GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation By The FDA" (Press release). Medical News Today. January 30, 2008. http://www.medicalnewstoday.com/articles/95590.php. Retrieved November 30, 2008.
- "Synta Pharmaceuticals press release". February 26, 2009.
- "Synta Announces Elesclomol Clinical Development to Resume". March 2, 2010.
- "Prous Science Molecule of the Month: Elesclomol". Thomson Reuters. December 2007. Retrieved November 30, 2008.
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.